{"id":"ncx-470-0-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Increased iris pigmentation"},{"rate":null,"effect":"Eyelash growth"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NCX 470 combines the intraocular pressure-lowering effects of a prostaglandin F analog with nitric oxide donation. Nitric oxide enhances aqueous humor drainage through both the conventional (trabecular) and unconventional (uveoscleral) pathways. This dual mechanism may provide superior efficacy compared to prostaglandin analogs alone in reducing intraocular pressure in glaucoma patients.","oneSentence":"NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:51.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04630808","phase":"PHASE3","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-11-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":696},{"nctId":"NCT05938699","phase":"PHASE2, PHASE3","title":"Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2023-12-12","conditions":"Open Angle Glaucoma","enrollment":18},{"nctId":"NCT04445519","phase":"PHASE3","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-06-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":691}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NCX 470"],"phase":"phase_3","status":"active","brandName":"NCX 470 0.1%","genericName":"NCX 470 0.1%","companyName":"Nicox Ophthalmics, Inc.","companyId":"nicox-ophthalmics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}